Molecular and immunohistochemical techniques provide insights that will allow us to tailor the management of patients with breast cancer. BRCA1 is becoming an important prognostic factor for breast cancer. The morphological features of tumors from patients with breast cancer associated with BRCA1 mutation include higher grade, with an excess of medullary carcinoma (Marcus et al., 1996). Tumors associated with BRCA1 mutation are more likely to be steroid hormone receptor (ER and PR) negative (Osin et al., 1998). The present study showed an alteration in BRCA1 mRNA expression in 40% of tissues studied, with a statistically significant relationship between BRCA1 mRNA expression and poor prognosis as well as high-tumor grade (P<0.05). This finding is consistent with a study demonstrating that alteration in BRCA1 gene expression significantly correlates with higher breast cancer histological grade (Lee, 2002). Grade is an independent prognostic indicator and is inversely related to outcome (Elston and Ellis, 1991). Several reports have indicated that a specific histopathological phenotype can be recognized in breast carcinoma occurring in women with germline mutations in BRCA1 (Elston and Ellis, 1991; Stratton, 1997). One of these studies reported an increased rate of ductal carcinoma in breast cancers associated with BRCA1 mutations (Elston and Ellis, 1991). Others reported an increase in the incidence of tumors with a medullary and atypical medullary pattern within the group of ductal carcinomas associated with BRCA1 mutations (Marcus et al., 1996; Stratton, 1997). The findings of the present study support the findings of these workers. However, 40% of breast cancers with alteration in BRCA1 mRNA in the study were mainly high-grade carcinoma. Moreover, this study showed an association between BRCA1 expression and negative ER and PR expression (statistically significant). Previous reports also showed that breast cancers associated with BRCA1 mutation were significantly more often ER and PR negative (Marcus et al., 1996; Lakhani et al., 2002). ER has become one of the most important prognostic and predictive markers for breast cancer (Lakhani et al., 2002). ER-positive tumors tend to grow more slowly, are better differentiated, and are associated with slightly better overall prognosis (Karp et al., 1997). PR status is also a good predictor of tumor responsiveness to therapy. Approximately 75% of ER/PR-positive tumors respond positively to endocrine therapy (Clark, 2000; Elledge and Fuqua, 2000). In addition to the above relationship with hormone receptors, the present study also demonstrated a positive relationship between overexpression of the protooncogene HER-2 in breast cancers with alteration of BRCA1 mRNA (33% of cases), one of which was CK5/6 positive. Our findings are in agreement with the study by Yoshikawa et al. (1999), who reported that breast cancers with reduced BRCA1 protein expression had a tendency toward overexpression of HER-2. This protooncogene is a biological marker for breast cancer, overexpression of which indicates poor prognosis. Furthermore, HER-2 is amplified in ∼20% of invasive cancers and has received interest because of its association with lymph node metastasis and its short relapse time, poor survival, and decreased response to endocrine and chemotherapy (Varley et al., 1987). Antibodies directed against the HER-2 protein have attracted a lot of attention because of the availability of the monoclonal antibody Herceptin for treatment of breast cancer (Slamon et al., 2001). Some studies have reported that breast cancers associated with BRCA1 mutations develop at a relatively early age (Elston and Ellis, 1991). Women carrying a BRCA1 or BRCA2 mutation are known to have an increased risk of developing contralateral primary breast cancer (Metcalfe et al., 2004), which is even more apparent among younger (age <50 years) women diagnosed with a primary breast carcinoma (Robson et al., 1998; Verhoog et al., 2000). In another study, a BRCA1 mutation carrier presented with metastatic disease 3.5 years after prophylactic mastectomy (no primary breast cancer found), suggesting the presence of an occult primary tumor that was never found, despite a thorough reexamination of the specimen at the time of presentation with the metastatic disease. This finding emphasizes the fact that, despite thorough examination of the mastectomy specimens, the presence of an occult breast cancer cannot be ruled out completely and indicates that a form of surveillance after prophylactic mastectomy might be relevant (Meijers-Heijboer et al., 2001). BRCA1 or BRCA2 mutation carriers and women from a hereditary breast/ovarian cancer family have a highly increased risk of developing breast cancer. Prophylactic mastectomy results in the greatest reduction in breast cancer risk (Heemskerk-Gerritsen et al., 2007).
There are no conflicts of interest.
Amirrad M, Al-Mulla F, Varadharaj G, John B, Saji T, Anim JT.BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters.Med Princ Pract2005;14:67–72.
Brekelmans CTM, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MMA, Bartels CCM, et al..Survival and prognostic factors in BRCA1-associated breast cancer.Ann Oncol2006;17:391–400.
Chen C-F, Li S, Chen Y, Chen P-L, Dave Sharp Z, Lee W-H.The nuclear localization sequences of the BRCA1 protein interact with the importin-α subunit of the nuclear transport signal receptor.J Biol Chem1996;271:32863–32868.
Clark GHarris JR.Prognostic and predictive factors.Diseases of the Breast2000.Philadelphia:Lippincott, Williams & Wilkins;489–514.
Dalton LW, Page DL, Dupont WD.Histologic grading of breast carcinoma: a reproducibility study.Cancer1994;73:2765–2770.
Easton DF, Ford D, Bishop DT, Haites N, Milner B, Allan L, et al..Breast and ovarian cancer incidence in BRCA1-mutation carriers.Am J Hum Genet1995;56:265–271.
El-Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A, et al..Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.Ann Surg Oncol2004;11:157–164.
Elledge RM, Fuqua SAHarris JR.Estrogen and progesterone receptors.Diseases of the breast2000.Philadelphia:Lippincott, Williams & Wilkins;471–488.
Elston CW, Ellis IO.Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.Histopathology1991;19:403–410.
Guerra I, Algorta J, Díaz De Otazu R, Pelayo A, Fariña J.Immunohistochemical prognostic index for breast cancer in young women.Mol Pathol2003;56:323–327.
Heemskerk-Gerritsen BAM, Brekelmans CTM, Menke-Pluymers MBE, Van Geel AN, Tilanus-Linthorst MMA, Bartels CCM, et al..Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam family cancer clinic.Ann Surg Oncol2007;14:3335–3344.
Hill ADK, Doyle JM, McDermott EW, O’Higgins NJ.Hereditary breast cancer.Br J Surg1997;84:1334–1339.
Jóhannsson OT, Idvall I, Anderson C, Borg A, Barkardóttir RB, Egilsson V, Olsson H.Tumour biological features of BRCA1-induced breast and ovarian cancer.Eur J Cancer1997;33:362–371.
Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD.Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.Cancer1997;80:435–441.
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF.The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.J Clin Oncol2002;20:2310–2318.
Lee W-Y.Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.Appl Immunohistochem Mol Morphol2002;10:310–315.
Lynch HT, Lynch J, Conway T, Watson P, Feunteun J, Lenoir G, et al..Hereditary breast cancer and family cancer syndromes.World J Surg1994;18:21–31.
Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al..Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.Cancer1996;77:697–709.
Meijers-Heijboer H, Van Geel B, Van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MBE, et al..Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.N Engl J Med2001;345:159–164.
Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al..Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.J Clin Oncol2004;22:2328–2335.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al..A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.Science1994;266:66–71.
Osin P, Crook T, Powles T, Peto J, Gusterson B.Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.Lancet1998;351:1487.
Parkin DM, Whelan SL, Ferlay J, Storm HH.Cancer incidence in fivecontinents vol. VIII
2000.Lyon, France:IARC Press.
Putti TC, Abd El-Rehim DM, Rakha EA, Paish CE, Lee AHS, Pinder SE, Ellis IO.Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis.Mod Pathol2005;18:26–35.
Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al..BRCA-associated breast cancer in young women.J Clin Oncol1998;16:1642–1649.
Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, et al..Location of BRCA1 in human breast and ovarian cancer cells.Science1996;272:123–126.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al..Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001;344:783–792.
Stratton MR.Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases.Lancet1997;349:1505–1510.
Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA.Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.Oncogene1987;1:423–430.
Vaughn JP, Davis PL, Jarboe MD, Huper G, Craig Evans A, Wiseman RW, et al..BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.Cell Growth Differ1996;7:711–715.
Verhoog LC, Brekelmans CTM, Seynaeve C, Meijers-Heijboer EJ, Klijn JGM.Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.Br J Cancer2000;83:384–386.
Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, et al..Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.Clin Cancer Res1999;5:1249–1261.